Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for MeiraGTx Holdings PLC (MGTX : NSDQ)

• Company Description    MeiraGTx Holdings plc focuses on operating as a holding company for MeiraGTx Limited which operates as a clinical stage gene therapy company. It develops novel gene therapy treatments for inherited and acquired disorders. The company's product pipeline consists of AAV-CNGB3, AAV-CNGA3, AAV-RPE65, AAV-RPGR, AAV-AQP1, AAV-AQP1 and AAV-UPF1 which are in clinical stage. MeiraGTx Holdings plc is based in New York. Number of Employees: 403

• Price / Volume Information    Yesterday's Closing Price: $13.89 Daily Weekly Monthly 20 Day Moving Average: 699,075 shares Shares Outstanding: 96.04 (millions) Market Capitalization: $1,334.04 (millions) Beta: 1.27 52 Week High: $15.35 52 Week Low: $6.62 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 6.68% 7.16% 12 Week 42.46% 39.43% Year To Date 74.72% 54.95%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 655 THIRD AVENUE SUITE 1115 - NEW YORK,NY 10017 USA ph: 646-860-7985 fax: - investors@meiragtx.com http://www.meiragtx.com

• General Corporate Information    Officers Alexandria Forbes - President and Chief Executive Officer and Director Keith R. Harris - Chairman of the Board and Director Richard Giroux - Chief Financial Officer Ellen Hukkelhoven - Director Lord Mendoza - Director Peer Information MeiraGTx Holdings PLC (CORR.) MeiraGTx Holdings PLC (RSPI) MeiraGTx Holdings PLC (CGXP) MeiraGTx Holdings PLC (BGEN) MeiraGTx Holdings PLC (GTBP) MeiraGTx Holdings PLC (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: G59665102 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/12/26 Share - Related Items Shares Outstanding: 96.04 Most Recent Split Date: (:1) Beta: 1.27 Market Capitalization: $1,334.04 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.46 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $0.30 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/12/26

• Fundamental Ratios P/E Current FY Estimate: 46.69 Trailing 12 Months: 19.56 PEG Ratio: - Price Ratios Price/Book: 5.96 Price/Cash Flow: - Price / Sales: 3.36 EPS Growth vs. Year Ago Period: 456.25% vs. Previous Quarter: 400.00% Sales Growth vs. Year Ago Period: 8,608.59% vs. Previous Quarter: 109,604.43% ROE 06/30/26 - 283.85 03/31/26 - - 12/31/25 - - ROA 06/30/26 - 29.39 03/31/26 - -54.96 12/31/25 - -53.33 Current Ratio 06/30/26 - 3.76 03/31/26 - 0.55 12/31/25 - 0.75 Quick Ratio 06/30/26 - 3.76 03/31/26 - 0.55 12/31/25 - 0.75 Operating Margin 06/30/26 - 19.87 03/31/26 - -151.12 12/31/25 - -140.31 Net Margin 06/30/26 - 19.87 03/31/26 - -151.12 12/31/25 - -140.31 Pre-Tax Margin 06/30/26 - 20.45 03/31/26 - -151.12 12/31/25 - -140.31 Book Value 06/30/26 - 2.33 03/31/26 - -0.63 12/31/25 - -0.07 Inventory Turnover 06/30/26 - - 03/31/26 - 46.66 12/31/25 - 21.03 Debt-to-Equity 06/30/26 - 0.46 03/31/26 - - 12/31/25 - - Debt-to-Capital 06/30/26 - 31.69 03/31/26 - - 12/31/25 - -

Powered by Zacks Investment Research ©